PDS Biotechnology

All the posts published.

PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine

Dec 21, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine Versamune® T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine   London, UK – 21 December 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, [...]

PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

Nov 11, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency London, UK – 11 November 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces [...]

PDS Biotech launch Merck Trials

Nov 10, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company")   PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients London, UK – 09 November 2020 – NetScientific [...]

PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101

Oct 27, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer London, UK – 26 October 2020 – NetScientific plc (AIM: NSCI), the life sciences and technology investment and commercialisation company, announces that it its portfolio company PDS Biotechnology Corporation ("PDS") [...]

PDS Announces Closing of $19m Offering

Aug 14, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) yesterday announced the closing of its previously announced [...]

PDS Announces Pricing of $16.5m Common Stock Offer

Aug 12, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) yesterday finalised pricing of its previously announced underwritten public offering which consisted of 6,000,000 shares of [...]

PDS Announces Proposed Offering of Common Stock

Aug 11, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) yesterday announced that it intends to offer and sell shares of its common stock in an underwritten public offering. [...]

PDS Biotechnology Announces Preclinical Data for PDS0203

Jul 27, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotechnology Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19 Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its [...]

PDS collaborator awarded grant for Versamune

Jul 14, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine   London, UK – 14 July 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) today announced that PDS Biotech collaborator, Professor [...]

PDS & Farmacore Announce Co-Development-PDS0204

Jun 18, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine   London, UK – 18 June 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) today announced a co-development agreement with Farmacore Biotechnology for Versamune®-CoV-2FC, [...]
PDS Biotechnology Archives - NetScientific